Orange Book product · Brand (NDA)
ESCITALOPRAM
ESCITALOPRAM OXALATE
At a glance
Aug 29, 2025
Approved
Brand (NDA)
Application
Not listed
TE code
None
Listed patents
Key dates
Approval
FDA approval date of this drug product.
Aug 29, 2025
10 mo ago
Today
Pharmaceutical detail
Active ingredient
ESCITALOPRAM OXALATE
Strength
EQ 15MG BASE
Dosage form
CAPSULE
Route
ORAL
TE code
Not listed
Application
NDA 219130
Product number
001
Marketing status
RX
Reference listed drug (RLD)
Yes
Reference standard (RS)
Yes
Active-ingredient family
View full familyThis is a reference-listed drug (RLD) — the basis for generic (ANDA) applications. Other products sharing this ingredient are listed below.
- 2002LEXAPROBrand (NDA)
NDA 021365 · ABBVIE
- 2002LEXAPROBrand (NDA)
NDA 021323 · ABBVIE
- 2026ESCITALOPRAM OXALATEGeneric (ANDA)
ANDA 091655 · MICRO LABS
- 2025ESCITALOPRAM OXALATEGeneric (ANDA)
ANDA 215177 · ASCENT PHARMS INC
- 2017ESCITALOPRAM OXALATEGeneric (ANDA)
ANDA 205619 · AMNEAL PHARMS
- 2016ESCITALOPRAM OXALATEGeneric (ANDA)
ANDA 202754 · MACLEODS PHARMS LTD
- 2015ESCITALOPRAM OXALATEGeneric (ANDA)
ANDA 078032 · PRINSTON INC
- 2015ESCITALOPRAM OXALATEGeneric (ANDA)
ANDA 203967 · ANTRIM PHARMS LLC
- 2015ESCITALOPRAM OXALATEGeneric (ANDA)
ANDA 077550 · NOVITIUM PHARMA
- 2013ESCITALOPRAM OXALATEGeneric (ANDA)
ANDA 090477 · CHARTWELL MOLECULAR
- 2012ESCITALOPRAM OXALATEGeneric (ANDA)
ANDA 077512 · AIPING PHARM INC
- 2012ESCITALOPRAM OXALATEGeneric (ANDA)
ANDA 202280 · JUBILANT CADISTA
Listed patents
No patents are listed against this product in the Orange Book. Listed patents reflect those the NDA holder submits under 21 U.S.C. 355 and are not exhaustive.
